1. Home
  2. SCYX vs VWAV Comparison

SCYX vs VWAV Comparison

Compare SCYX & VWAV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

HOLD

Current Price

$5.05

Market Cap

44.4M

Sector

Health Care

ML Signal

HOLD

Logo VisionWave Holdings Inc.

VWAV

VisionWave Holdings Inc.

N/A

Current Price

$4.29

Market Cap

36.4M

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
SCYX
VWAV
Founded
1999
2024
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
44.4M
36.4M
IPO Year
2014
2025

Fundamental Metrics

Financial Performance
Metric
SCYX
VWAV
Price
$5.05
$4.29
Analyst Decision
Strong Buy
Analyst Count
3
0
Target Price
★ $36.33
N/A
AVG Volume (30 Days)
259.2K
★ 1.4M
Earning Date
11-04-2026
08-19-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 61.36
N/A
EPS
★ N/A
N/A
Revenue
★ $257,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$906.41
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.26
52 Week High
$6.09
$225.00

Technical Indicators

Market Signals
Indicator
SCYX
VWAV
Relative Strength Index (RSI) 54.63 47.84
Support Level $4.65 $0.56
Resistance Level $5.44 $7.40
Average True Range (ATR) 0.43 1.55
MACD 0.07 -0.12
Stochastic Oscillator 68.31 34.58

Price Performance

Historical Comparison
SCYX
VWAV

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About VWAV VisionWave Holdings Inc.

VisionWave Holdings Inc is a technology company focused on the development and commercialization of artificial intelligence (AI) and autonomous solutions across air, ground and sea environments. Through its subsidiary, the Company designs and deploys technologies including radars, radio frequency (RF) sensing, unmanned aerial and ground systems, remote weapon stations and active protection systems for defense, military, homeland security and industrial applications. Its proprietary AI engine supports autonomous decision-making and product lines at various stages of development and commercialization. Revenue is generated through product sales, technology licensing, strategic alliances and joint ventures, with products including C-UAS, multi-purpose autonomous UAS and Vision-AI technology.

Share on Social Networks: